Clinical Trial Update: Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating SHR-A1811 in patients with HER2-expressing or HER2-amplified biliary tract cancer; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma
• Gallbladder Cancer

Drugs mentioned

• SHR-A1811

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: HER2 Expression / Amplification in Patients With Biliary Tract Cancer | Phase 2 | Status: RECRUITING